21 related articles for article (PubMed ID: 38302969)
1. Sustained activation of autophagy suppresses adipocyte maturation via a lipolysis-dependent mechanism.
Zhang X; Wu D; Wang C; Luo Y; Ding X; Yang X; Silva F; Arenas S; Weaver JM; Mandell M; Deretic V; Liu M
Autophagy; 2020 Sep; 16(9):1668-1682. PubMed ID: 31840569
[TBL] [Abstract][Full Text] [Related]
2. Depletion of enhancer zeste homolog 2 (EZH2) directs transcription factors associated with T cell differentiation through epigenetic regulation of Yin Yang 1(YY1) in combating non-small cell lung cancer (NSCLC).
Chandnani N; Choudhari VS; Talukdar R; Rakshit S; Shanmugam G; Guchait S; Gupta I; George M; Sarkar K
Med Oncol; 2023 May; 40(7):185. PubMed ID: 37212947
[TBL] [Abstract][Full Text] [Related]
3. Yin Yang 1 facilitates hepatocellular carcinoma cell lipid metabolism and tumor progression by inhibiting PGC-1β-induced fatty acid oxidation.
Li Y; Kasim V; Yan X; Li L; Meliala ITS; Huang C; Li Z; Lei K; Song G; Zheng X; Wu S
Theranostics; 2019; 9(25):7599-7615. PubMed ID: 31695789
[TBL] [Abstract][Full Text] [Related]
4. YY1 binds to the E3' enhancer and inhibits the expression of the immunoglobulin κ gene via epigenetic modifications.
Zhou X; Xian W; Zhang J; Zhu Y; Shao X; Han Y; Qi Y; Ding X; Wang X
Immunology; 2018 Dec; 155(4):491-498. PubMed ID: 30098214
[TBL] [Abstract][Full Text] [Related]
5. RPTOR blockade suppresses brain metastases of NSCLC by interfering the ceramide metabolism via hijacking YY1 binding.
Lin Y; Wu Y; Zhang Q; Tu X; Chen S; Pan J; Xu N; Lin M; She P; Niu G; Chen Y; Li H
J Exp Clin Cancer Res; 2024 Jan; 43(1):1. PubMed ID: 38163890
[TBL] [Abstract][Full Text] [Related]
6. YY1 Is a Key Player in Melanoma Immunotherapy/Targeted Treatment Resistance.
Kwiatkowska D; Mazur E; Reich A
Front Oncol; 2022; 12():856963. PubMed ID: 35719931
[TBL] [Abstract][Full Text] [Related]
7. Are immune checkpoint blockade monoclonal antibodies active against CNS metastases from NSCLC?-current evidence and future perspectives.
O'Kane GM; Leighl NB
Transl Lung Cancer Res; 2016 Dec; 5(6):628-636. PubMed ID: 28149757
[TBL] [Abstract][Full Text] [Related]
8. Correction: RPTOR blockade suppresses brain metastases of NSCLC by interfering the ceramide metabolism via hijacking YY1 binding.
Lin Y; Wu Y; Zhang Q; Tu X; Chen S; Pan J; Xu N; Lin M; She P; Niu G; Chen Y; Li H
J Exp Clin Cancer Res; 2024 Feb; 43(1):37. PubMed ID: 38302969
[No Abstract] [Full Text] [Related]
9. Immunotherapy in NSCLC patients with brain metastases. Understanding brain tumor microenvironment and dissecting outcomes from immune checkpoint blockade in the clinic.
Vilariño N; Bruna J; Bosch-Barrera J; Valiente M; Nadal E
Cancer Treat Rev; 2020 Sep; 89():102067. PubMed ID: 32682248
[TBL] [Abstract][Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
